(Q36980432)

English

Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer

scientific article published on January 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

1 reference

based on heuristic

inferred from title

thromboembolism

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Joseph Sgouros

1

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Anthony Maraveyas

2

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Acta Oncologica

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

337-346

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

Locally advanced pancreatic cancer: current therapeutic approach

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Adjuvant therapy in pancreatic cancer: historical and current perspectives

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Nervous system involvement by pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Chemotherapy for colorectal cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Pancreatic cancer and thromboembolic disease.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

The effect of low molecular weight heparin on survival in patients with advanced malignancy

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Characterization of dihydropyrimidine dehydrogenase on immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Incidental detection of pulmonary emboli on routine MDCT of the chest

1 reference

https://api.crossref.org/works/10.1080%2F02841860701687267

21 January 2018

Identifiers

10.1080/02841860701687267

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

release_accggtg7wrgxpkjk6gecfllufq

1 reference

https://api.fatcat.wiki/v0/release/accggtg7wrgxpkjk6gecfllufq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36980432&oldid=2043620718"